Thanks. I was informed by private email from one of the shareholders who has been corresponding that Dr. Mullan is no longer CEO of Roskamp, but is CEO of Archer. Dr. Crawford is now CEO at Roskamp. I associate her closely with anatabine because she is the doc leading research on TBI and GFI. I have not heard anything new on that, but I think with continued federal grants, she would want to continue that work. As Mullan once told me, Roskamp, as a non-profit, can use anatabine even though it does not own the IP. So where does that leave Mullan and Archer? I also would be surprised if Mullan is NOT interested in anatabine. Whether Mullan would feel any loyalty to other RCPIQ shareholders is up for discussion. Very complicated!
